Epoch Biodesign
PrivateLast Round
Strategic
Mar 25, 2026
Total Funding Raised
$45.8M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Epoch Biodesign is a biotechnology company that develops AI-designed enzymes for the biorecycling of mixed plastics and textiles.
Sector
Energy & Sustainability
Verticals
Biotechnology, Circular Economy, Sustainable Materials, Clean Manufacturing, Supply Chain
Business Model
B2B
Customer Profile
Data as a Service, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Epoch Biodesign Comparables
Compare Epoch Biodesign with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Samsara Eco | 91% | |
| Evoralis | 82% | |
| Breaking | 81% |
Epoch Biodesign Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Mar 25, 2026 | ||||
| Grant | Mar 5, 2025 | ||||
| Series A | Mar 5, 2025 | ||||
| Seed | Jun 22, 2022 | ||||
| Pre Seed | Jan 13, 2021 | ||||
Pre Seed | Dec 1, 2020 |
Epoch Biodesign Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovate UK | Grant |
| Amadeus Capital Partners | Seed |
| Mundi Ventures | Series A |
| Ascension Ventures | Pre Seed |
| Voyagers.io | Seed |
| Plug and Play Tech Center | Pre Seed |
| Happiness Capital | Series A, Strategic |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 5, 2026
Grew 34% QoQ, from 62 to 83 employees.
- Aug 24, 2026
Grew 40% QoQ, from 57 to 80 employees.
Recent news
Latest coverage and updates
- hiresOct 13, 2026
Epoch Biodesign Ltd. appoints Jamie Scott as Chief Operating Officer to lead production operations and supply chain as it expands manufacturing capacity and prepares for commercial-scale nylon 6,6 recycling.
- is_developingOct 12, 2026
Epoch Biodesign Ltd. signs an MOU with INVISTA to develop post-consumer recycled nylon 6,6 at commercial scale in Feb '26.
- hiresOct 12, 2026
Epoch Biodesign Ltd. appoints Jerry Grunewald as senior advisor
- expands_facilitiesAug 7, 2026
Epoch Biodesign Ltd. acquires a nylon 6,6 manufacturing facility in Blanes, Spain, for €4m, adding 52,000 tonnes of annual capacity and 60 jobs.
- invests_into_assetsAug 6, 2026
Epoch Biodesign Ltd. invested into assets: 52,000-tonne-a-year in the amount of $4.62M in Blanes, 17300, Spain, Southern Europe, Europe on Jan 1st '26.
Epoch Biodesign Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Epoch Biodesign's valuation, stock price, and market status.
Is Epoch Biodesign a public or private company?
Epoch Biodesign is a private company.
What is the current stock price of Epoch Biodesign?
Epoch Biodesign is a private company, so its shares have no public market price. Caplight tracks Epoch Biodesign's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Epoch Biodesign worth (valuation)?
Valuation information for Epoch Biodesign is not publicly available.
Can I buy Epoch Biodesign stock?
Epoch Biodesign shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Epoch Biodesign's last funding round?
Epoch Biodesign's most recent funding round was Strategic on March 25, 2026.
Who are the main investors in Epoch Biodesign?
Key investors in Epoch Biodesign include Extantia, Lowercarbon Capital.
Will Epoch Biodesign IPO soon?
No public IPO plans have been announced for Epoch Biodesign.
How can I track Epoch Biodesign secondary market activity?
Caplight tracks bids, offers, and trades in Epoch Biodesign's shares on secondary markets.